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INTRODUCTION 
In late March and early April 2009, an outbreak of H1N1 
influenza A virus infection was detected in Mexico, with 
subsequent cases observed in many other countries (1) (2).The 
pandemic that began in March 2009 was caused by an H1N1 
influenza A virus that represents a quadruple reassortment of two 
swine strains, one human strain, and one avian strain of influenza. 
On June 11, 2009, the World Health Organisation (WHO) signaled 
that a global pandemic of novel influenza A (H1N1) was underway 
by raising the worldwide pandemic alert level to Phase 6. This was 
the first of the kind declared by WHO in the past 70 years. This 
action was a reflection of the spread of the new H1N1 virus. At the 
same time, more than 70 countries have reported cases of novel 
influenza A (H1N1) infection and there were ongoing community 
level outbreaks of novel H1N1 in different parts of the world (3). 
The pandemic started in India in the month of August 2009 and the 
index cases were reported from Pune and soon the epidemic spread 
itself to other parts of the country. With the fresh cases, as on 10th 
March 2010 the total number of H1N1 positive cases confirmed by 
both government and private laboratories in India had risen to 
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29,880 and the total number of swine flu deaths had risen  to 1401. 
This epidemic was notoriously seen to affect the younger 
population in the age group of 15-40 years thereby affecting the  
workhouse of the country. Present analysis is our experience from a 
tertiary care referral institute admitting H1N1  positive cases. This 
is a prospective study of reported cases admitted   from August 
2009 to January 2010.  
 
WHO ALERT LEVEL’S FOR INFLUENZA PANDEMICS 
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AIMS AND OBJECTIVES  
1) To study the clinical profile of the H1N1 influenza cases 
attending Madras Medical College & Government General 
Hospital, Chennai and Institute of child health,  Egmore , 
Chennai . 
2) To study the impact of H1N1 infection on pregnancy 
outcome. 
3) To evaluate the mortality rates among hospitalized patients 
with H1N1 influenza.  
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REVIEW OF LITERATURE  
HISTORICAL  PERSPECTIVE  
Illness with influenza in pigs was first recognized during the 
influenza pandemic of 1918 to 1919, and a swine influenza virus 
was first isolated from a human in 1974 (4) (5) (6). In 1976, swine 
influenza virus caused a respiratory illness with one fatality among 
13 soldiers in Fort Dix, New Jersey  (7) . No exposure to pigs was 
found. A subsequent epidemiologic study showed that up to 230 
soldiers had been infected with the virus (4), (8). 
Between 1958 and 2005, 37 cases of swine influenza among 
civilians were reported (4). Six cases (17 percent) resulted in death. 
Forty-four percent of infected individuals had known exposure to 
pigs. Cases were reported in the United States, former 
Czechoslovakia, the Netherlands, Russia, Switzerland, and Hong 
Kong. 
CASE DEFINITIONS  
The following case definitions have been provided by the 
United States Centers for Disease Control and Prevention (4): 
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1) Influenza-like illness (ILI) is defined as fever (temperature of 
100ºF [37.8ºC] or greater) with cough or sore throat in the 
absence of a known cause other than influenza.  
2) A confirmed case of pandemic H1N1 influenza A is defined 
as an individual with an ILI with laboratory-confirmed H1N1 
influenza A virus detected by real-time reverse transcriptase 
(rRT)-PCR or culture.  
3) Pandemic H1N1 influenza A may be suspected in an 
individual who does not meet the definition of confirmed 
pandemic H1N1 influenza A, but has an ILI and an 
epidemiologic link. 
VIROLOGY  
Influenza subtypes: 
Clinical influenza can be caused by several different 
influenza subtypes, although H1N1 is the most common 
subtype implicated in both swine and human infections  (9). 
Human cases of swine H3N2 influenza A virus infection has 
been reported rarely(4). Other subtypes that have circulated in 
pigs include H1N2, H3N1, and H3N2. 
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Genetic and antigenic characterization  
 The pandemic that began in March 2009 was caused by an 
H1N1 influenza A virus that had not been recognized 
previously in pigs or humans, although six of its eight 
gene segments were similar to ones previously detected in 
triple reassortant swine influenza viruses in pigs in North 
America (10). This strain represents a quadruple 
reassortment of two swine strains, one human strain, and 
one avian strain of influenza (11) (12) (13). The largest 
proportion of genes comes from swine influenza viruses 
(30.6 percent from North American swine influenza 
strains, 17.5 percent from Eurasian swine influenza 
strains), followed by North American avian influenza 
strains (34.4 percent) and human influenza strains (17.5 
percent) (14). 
 Analysis of the antigenic and genetic characteristics of the 
pandemic H1N1 influenza A virus demonstrated that its 
gene segments have been circulating for many years, 
suggesting that lack of surveillance in swine is the reason 
that this strain had not been recognized previously (15). 
One of the swine influenza viruses that contributed gene 
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segments to the strain causing the 2009 pandemic is 
thought to have derived from the strain that caused the 
1918 influenza pandemic (16). 
 Among the 2009 pandemic H1N1 influenza A viruses 
sequenced, each gene segment had high sequence identity 
(99.9 percent), suggesting that introduction into humans 
was either a single event or multiple events of genetically 
similar viruses (11). Furthermore, the H1N1 influenza A 
viruses causing the 2009 pandemic were found to be 
antigenically homogeneous. . Phylogenetic  analysis has 
suggested that initial transmission to humans occurred 
several months before the outbreak was recognized (15). 
 Sequence analysis of isolates from the United States and 
Mexico did not identify molecular features known to 
confer increased transmissibility or virulence (11). 
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ANTIGENIC DRIFT AND SHIFT 
S.NO ANTIGENIC  DRIFT ANTIGENIC SHIFT 
1. Gradual change over a 
period 
Sudden complete change 
2. Involves point 
mutations 
Genetic recombination of human 
with animal/avian virus 
3. Responsible for 
frequent epidemics, 
Leads to novel subtype different 
from both parent viruses 
 
INFLUENZA VIRUS – 3 TYPES 
 
Type A Type B Type C 
Causes significant 
disease: epidemics, 
pandemics 
Causes significant 
disease: milder 
epidemics 
Does not cause 
significant disease 
Infects both humans 
and other species 
Limited to humans Limited to humans 
Frequent antigenic 
variations 
Infrequent antigenic 
variations 
Antigenically stable 
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TRANSMISSION 
PERSON-TO-PERSON TRANSMISSION  
 Influenza virus is present in respiratory secretions of infected 
persons. As a result, influenza virus can be transmitted through 
sneezing and coughing via large-particle droplets (17,18). 
Transmission via contact with surfaces that have been 
contaminated with respiratory droplets or by aerosolized small-
particle droplets may also occur, although these modes of 
transmission have not been proven . In addition to respiratory 
secretions, certain other bodily fluids (eg, diarrheal stool) should 
also be considered potentially infectious. 
 In contrast to previous outbreaks of swine influenza viruses 
described above, the pandemic of H1N1 influenza A infection that 
began in March 2009 appears to involve sustained human-to-
human transmission, as suggested by the large numbers of patients 
with respiratory illnesses identified within a short period of time at 
various locations around the world (19). Several of the isolates 
causing disease in the United States have been found to be nearly 
genetically identical to isolates in Mexico, supportive of person-to-
person transmission (20). 
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 Based on analysis by the World Health Organization using 
early data from the outbreak in Mexico and other countries, 
transmissibility appears substantially higher compared with 
seasonal influenza (21). In one study, the secondary attack 
rate of the strain causing this pandemic was estimated to be 
22 to 33 percent, compared with 5 to 15 percent for seasonal 
influenza (22). In another study, the secondary attack rate in 
households was estimated to be 27 percent, and an infected 
school child was estimated to infect 2.4 other children within 
the school (23). In contrast to the two studies cited above  
(22, 23), the United States Centers for Disease Control and 
Prevention has reported that the attack rate observed in the 
US is similar to that in seasonal influenza (24). 
 Infection control and social distancing measures are 
important in the prevention of swine transmission .  
INCUBATION PERIOD 
Although the precise incubation period has not been 
established for pandemic H1N1 influenza A infection, it could 
range from one to seven days, and most likely from one to four 
days (18). 
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SHEDDING  
Since the duration of shedding of pandemic H1N1 influenza 
A virus is currently unclear, the estimated duration of shedding is 
based upon what is known for seasonal influenza virus (25). 
Immunocompetent patients with pandemic H1N1 influenza A virus 
infection are likely to be contagious from one day prior to the 
development of signs and symptoms until resolution of fever (25). 
Longer periods of shedding may occur in children  
(especially young infants), elderly adults, patients with chronic 
illnesses, and immunocompromised hosts.  
ROLE OF PIGS  
 Pigs play an important role in interspecies transmission of 
influenza virus. Susceptible pig cells possess receptors for 
both avian (alpha 2-3-linked sialic acids) and human 
influenza strains (alpha 2-6-linked sialic acids), which allow 
for the reassortment of influenza virus genes from different 
species if a pig cell is infected with more than one strain (26-28).  
 Since the late 1990s, triple reassortment swine influenza A 
viruses containing genes from swine, human, and avian 
strains of influenza have been detected among swine herds in 
North America (29-31). Eleven sporadic cases of triple 
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reassortment swine  influenza A viruses were detected in the 
United States between December 2005 and February 
2009(29). Nine patients had exposure to pigs. 
 It is not clear yet how this virus arose or was initially 
transmitted to humans. On May 2, 2009, the Canadian 
government reported the identification of pandemic H1N1 
influenza A from a swine herd in Alberta, Canada . It is 
suspected that the pigs became infected following exposure to 
a farm worker who had recently visited Mexico and had 
developed an influenza-like illness. 
 There is no risk of becoming infected with influenza virus 
from eating pork. 
CLINICAL MANIFESTATIONS  
The signs and symptoms of influenza caused by pandemic 
H1N1 influenza A virus are similar to those of seasonal influenza, 
although gastrointestinal manifestations appear to be more common 
with pandemic H1N1 influenza A(18,19 ,22). The severity appears 
to be less than what was observed during the influenza pandemic of 
1918 to 1919 (21). 
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Signs and symptoms:  
The most common clinical findings of the 2009 H1N1 
influenza A pandemic have  been fever, cough, sore throat, malaise, 
and headache; vomiting and diarrhea have also been common, both 
of which are unusual features of seasonal influenza (32). Other 
frequent findings have included chills, myalgias, and 
arthralgias(18).In New York City, 95 percent of patients with 
pandemic H1N1 influenza A have met the case definition for 
influenza-like illness (subjective fever plus cough and/or sore 
throat) (18). In contrast, approximately one third of patients seen at 
two hospitals in Mexico had no fever at presentation (33). Certain 
groups, such as infants, elderly individuals, and immuno-
compromised hosts, may have atypical presentations. Among 268 
patients in the United States requiring hospitalization for pandemic 
H1N1 influenza A infection, clinical findings included fever (93 
percent), cough (83 percent), shortness of breath (54 percent), 
fatigue or weakness (40 percent), chills (37 percent), myalgias  (36 
percent), rhinorrhea (36 percent), sore throat (31 percent), headache 
(31 percent), vomiting (29 percent), wheezing (24 percent), and 
diarrhea (24 percent) . 
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Children: 
Young children are less likely to have the usual influenza 
signs and symptoms, such as fever and cough (34). Infants may 
present with fever and lethargy, and may not have cough or other 
respiratory symptoms. Symptoms of severe disease in infants and 
young children may include apnea, tachypnea, dyspnea, cyanosis, 
dehydration, altered mental status, and extreme irritability.Young 
children (eg, <5 years of age) are at increased risk for influenza 
complications (34, 35).  
High Risk Adults: 
Among  553 patients with confirmed or probable pandemic 
H1N1 influenza A in California, the most common risk factors for 
influenza complications were chronic lung disease (asthma or 
chronic obstructive pulmonary disease, 37 percent), 
immunosuppressive conditions (17 percent), cardiac disease (17 
percent), pregnancy (17 percent), diabetes mellitus (13 percent), 
and obesity (13 percent) (36).  
Although elderly patients are considered to be at an increased 
risk for complications of influenza, pandemic H1N1 influenza A 
infections in such individuals have been uncommon to date possibly 
as a result of preexisting immunity against antigenically similar 
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influenza viruses that circulated prior to 1957(24) . In one study, 39 
of 115 (34 percent) of individuals born before 1950 had preexisting  
microneutralization titers ≥80 against pandemic H1N1 influenza, 
whereas only 4 of 107 (4 percent) of  individuals born after 1980 
had titers ≥40 (27). Microneutralization titers ≥80 to 160 in adults 
and ≥40 in children often correlate with at least a 50 percent 
decrease in risk for influenza infection or disease, but whether 
these titers offer partial protection against pandemic H1N1 
influenza A virus infection or disease is unclear (28).  
DIAGNOSIS  
 Guidelines for the diagnosis of pandemic H1N1 influenza A virus 
have been released by the United States Centers for Disease Control 
and Prevention (CDC) (35).  
Whom to test ?  
 Most patients with an uncomplicated influenza-like illness 
who reside in areas where influenza viruses are known to be 
circulating do not need to be tested for influenza infection. 
Recommendations regarding whom to test may differ by state or 
community. 
Patients in whom influenza testing should be considered 
 Hospitalized patients with suspected influenza infection  
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 Patients for whom a diagnosis of influenza will affect 
decisions regarding clinical care, infection control, or 
management of close contacts.  
 Individuals who died of acute illness in whom influenza 
was suspected.  
Specimens: 
To establish the diagnosis of pandemic H1N1 influenza A, an 
upper or lower respiratory sample should be collected . Appropriate 
specimens include: 
 Nasopharyngeal swab  
 Nasal aspirate, wash, or swab  
 Endotracheal aspirate (in intubated patients)  
 Bronchoalveolar lavage (BAL) fluid  
 Combined nasopharyngeal or nasal swab with oropharyngeal swab  
In patients with severe pneumonia who are suspected of being 
infected with influenza and who are intubated or undergoing 
bronchoscopy, lower respiratory samples (endotracheal aspirate or 
BAL fluid) should be obtained and tested for influenza infection. 
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For proper specimen collection, instructions in the test's 
package insert should be followed. Furthermore, specimens should 
be obtained as soon as possible following the onset of symptoms. 
Swabs with a synthetic tip (eg, polyester or Dacron) and an 
aluminum or plastic shaft should be used. Swabs with cotton tips 
and wooden shafts are not recommended. Swabs made of calcium 
alginate are not acceptable. The collection vial in which the swab is 
placed should contain 1 to 3 mL of viral transport media. 
Specimens should be placed in viral transport media and 
placed on ice (4ºC) or refrigerated immediately for transportation to 
the laboratory. Once the samples arrive in the laboratory, they 
should be stored either in a refrigerator at 4ºC or in a -70ºC freezer. 
If a -70ºC freezer is not available, they should be kept refrigerated. 
Refrigerated samples should ideally be processed within 24 hours, 
and should not be stored for >72 hours. 
Diagnostic tests: 
 Real-time reverse transcriptase (RT)-PCR  is the most 
sensitive and specific test for the diagnosis of pandemic 
H1N1 influenza A virus infection (35).  
 Isolation of pandemic H1N1 influenza A virus using culture 
is also diagnostic, but culture is usually too slow to help 
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guide clinical management. A negative viral culture does not 
exclude pandemic H1N1 influenza A infection. 
 Several rapid antigen and immunofluorescent antibody tests 
are available for the diagnosis of influenza virus infection. 
However, the sensitivity of these tests varies widely, and 
although some assays are able to distinguish between 
influenza A and B viruses, they are not able to distinguish 
between pandemic and seasonal strains of H1N1 influenza A. 
Polymerase chain reaction: 
 Nucleic acid amplification tests, such as real-time reverse 
transcriptase (rRT)-PCR, are the most sensitive and specific 
tests for the diagnosis of influenza virus infection (35). 
 However, they may not be readily available and/or may 
require several days for processing since many hospitals and 
clinics must send samples to be processed at public health or 
commercial laboratories. Test performance depends on the 
individual rRT-PCR assay used. 
 The United States Food and Drug Administration has 
authorized several rRT-PCR assays for the diagnosis of 
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pandemic H1N1 influenza A infection under an Emergency 
Use Authorization (36). 
Rapid antigen tests: 
 Clinicians may consider using rapid influenza antigen tests as 
part of their evaluation of patients suspected of having 
pandemic H1N1 influenza A, but results should be interpreted 
with caution (38), (39).  
 Certain rapid influenza antigen tests that are commercially 
available can distinguish between influenza A and B viruses, 
but cannot distinguish among different subtypes of influenza 
A (eg, pandemic H1N1 influenza A versus seasonal H1N1 or 
H3N2 influenza A).  
 Confirmation of pandemic H1N1 influenza A infection can 
only be made by real-time reverse-transcriptase (rRT)-PCR or 
culture. 
 The sensitivity of rapid antigen testing for pandemic H1N1 
influenza A virus infection has ranged from 10 to 70 percent 
compared with rRT-PCR (37-42). Thus, a negative result does 
not rule out infection.  
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 The specificity of rapid antigen testing has generally been 
>95 percent (35), although in one study it was only 86 
percent (41). 
 Among 39 patients with pandemic H1N1 influenza A 
confirmed by    rRT-PCR, 20 had a positive rapid antigen test 
using the QuickVue Influenza A+B (Quidel) assay 
(sensitivity 51 percent)(38).  
 Twelve of 19 patients who had seasonal H1N1 influenza 
confirmed by rRT-PCR had a positive rapid antigen test 
(sensitivity 63 percent). 
 In the same study, the specificity of rapid antigen testing was 
99 percent for patients with either the pandemic strain or a 
seasonal strain of H1N1 influenza A.  
Immunofluorescent antibody testing: 
 Direct or indirect immunofluorescent antibody testing (DFA 
or IFA) can distinguish between influenza A and B, but does 
not distinguish among different influenza A subtypes (35).  
 In one study, among 42 samples that were positive for 
pandemic H1N1 influenza A by real-time reverse-
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transcriptase polymerase chain reaction, 39 were positive by 
direct fluorescent antibody testing (43).  
 However, a negative DFA or IFA does not exclude pandemic 
H1N1 influenza A infection since larger studies are required 
to define the sensitivity to detect this virus. 
Choice of test: 
 Most patients with an uncomplicated influenza-like illness 
who reside in areas where influenza viruses are known to be 
circulating do not need to be tested for influenza infection .  
 However, among patients for whom a diagnosis of influenza 
will affect decisions regarding clinical care, infection control, 
or management of close contacts, it is reasonable to use a 
rapid antigen or immunofluorescence antibody test. 
 In regions where the majority of circulating influenza viruses 
are known to be pandemic H1N1 influenza A, a positive 
result using one of these assays can be presumed to indicate 
infection with pandemic H1N1 influenza A. 
 If identification of pandemic H1N1 influenza A is required, 
such as in pregnant patients and those with severe 
immunosuppression, then real-time reverse transcriptase 
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polymerase chain reaction (rRT-PCR) testing should be 
performed. 
 In addition, rRT-PCR testing should be performed in 
hospitalized patients with suspected influenza infection who 
have a negative rapid antigen or immunofluorescence 
antibody test. 
 Influenza subtype testing with rRT-PCR or viral culture 
should also be prioritized for use in individuals who have 
died from suspected or confirmed influenza infection. 
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COMPLICATIONS OF H1N1 VIRUS INFECTION: 
 Pneumonia 
 Acute respiratory distress syndrome (ARDS) 
 Multi-organ failure 
 Cardiac and renal dysfunction  
 Gastrointestinal involvement  
 Sepsis-like syndrome, shock 
 Reye’s syndrome 
 TREATMENT 
High risk groups 
High risk groups for the development of complications of 
pandemic H1N1 influenza A are thought to be similar to those 
defined for seasonal influenza. They are  (43)- (49): 
 Children younger than 5 years of age, but especially those 
younger than 2. (48) 
 Individuals of 65 years of age or older:- Although individuals 
≥65 years of age who become infected with H1N1 influenza 
virus are thought to be at increased risk for complications, 
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this age group appears to be at lower risk of becoming 
infected with pandemic H1N1 influenza virus compared with 
younger persons, presumably because of immunity 
(antibodies) related to previous exposure to related virus 
strains. Thus, the US Centers for Disease Control and 
Prevention recommends that members of this age group who 
do not have other high-risk conditions have a low priority for 
vaccination with the pandemic H1N1 influenza virus vaccine.  
 Pregnant women  
 Individuals younger than 19 years of age who are receiving 
long-term aspirin therapy and who therefore might be at risk 
for Reye syndrome after influenza virus infection. 
 Individuals of any age with chronic medical conditions  
requiring ongoing medical care. They include   
o Cardiovascular disease, except isolated hypertension  
o Active malignancy  
o Chronic renal insufficiency  
o Chronic liver disease  
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o Diabetes mellitus 
o Hemoglobinopathies such as sickle cell disease  
o Immunosuppressive states. 
o Individuals who have any condition that can compromise 
handling of respiratory secretions (eg, cognitive 
dysfunction, spinal cord injuries, seizure disorders, 
neuromuscular disorders, cerebral palsy, metabolic 
conditions) 
o Children with an underlying metabolic disorder, such as 
medium-chain acyl-CoA dehydrogenase deficiency, who 
are unable to tolerate prolonged fasting 
Obesity and H1N1 influenza: 
 Obesity has not been recognized as a risk factor for severe 
seasonal influenza. 
 But cases of severe pandemic H1N1 influenza A, including 
pneumonia and acute respiratory distress syndrome, have 
been reported in obese individuals without known underlying 
conditions (50) (51).  
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Antiviral therapy: 
 Therapy should be started as soon as possible, since evidence 
of benefit is strongest for seasonal influenza when treatment 
is started within 48 hours of illness onset (47), (48) .  
 Furthermore, in a study of 272 patients requiring 
hospitalization for pandemic H1N1 influenza A in the United 
States between April and mid-June 2009, the receipt of 
antiviral drugs within two days after the onset of illness was 
significantly associated with a positive outcome in a 
multivariable model (53). 
 Some studies of hospitalized patients have demonstrated 
benefit even when therapy for seasonal influenza is started 
>48 hours after onset of illness.  
 In patients who are more than mildly ill,  initiate therapy even 
past 48 hours of symptoms (48). 
Resistance Patterns: 
 The vast majority of strains of pandemic H1N1 influenza A 
virus circulating in 2009 appear sensitive in vitro to the 
neuraminidase inhibitors, oseltamivir and zanamivir, but all 
strains tested have been resistant to amantadine and 
rimantadine (54)- (56). 
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  However, there are no reported studies yet on the clinical 
benefits of antiviral therapy. 
 As of September 2009, 99 percent of influenza isolates 
circulating in the United States were pandemic H1N1 
influenza A, the vast majority of which are sensitive to 
oseltamivir (48).  
 A notable difference between pandemic and seasonal strains 
of H1N1 influenza A is the resistance pattern to oseltamivir.  
 The low rate of oseltamivir resistance among pandemic H1N1 
influenza A strains to date contrasts with the extremely high 
rate among seasonal H1N1 influenza A strains.  
 A small minority of isolates of pandemic H1N1 influenza 
virus with resistance to oseltamivir have been detected from 
patients in Japan, the United States, China, Hong Kong, 
Singapore, Denmark, and Canada (61). 
  Several patients had been taking oseltamivir prophylaxis 
before becoming ill.  
 No tested isolates have been resistant to zanamivir, and most 
of the patients whose clinical courses have been reported 
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recovered without complications (56),(58). One severely 
immunocompromised patient remained hospitalized at the 
time her case was reported (59). 
Indications for antiviral therapy: 
 All hospitalized individuals with confirmed or suspected 
influenza virus infection (either pandemic or seasonal strains).  
 Individuals with confirmed or suspected influenza virus 
infection who are severely ill, such as those with lower 
respiratory tract infection (eg. dyspnea, tachypnea, 
unexplained oxygen desaturation), and those who are showing 
signs of rapid clinical deterioration.  
 Individuals with obesity (particularly those with morbid 
obesity) may be at increased risk of hospitalization and death 
due to pandemic H1N1 influenza infection; many obese 
persons have underlying conditions that increase the risk of 
influenza complications, such as diabetes mellitus, asthma, 
chronic respiratory illness, or liver disease. Thus, patients 
with morbid obesity (BMI >40) and possibly those with 
obesity (BMI 30 to 39) with suspected or confirmed influenza 
virus infection should be carefully evaluated for the presence 
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of conditions that confer an increased risk of influenza 
complications. If any such conditions are present, treatment 
should be given.  
Antiviral therapy should be considered for: 
 Outpatients with confirmed or suspected influenza virus 
infection who are at increased risk for complications. 
 During the current pandemic, patients with mild illness do not 
need to be tested or treated unless they have risk factors for 
complications (48). Patients who are recovering from 
influenza generally do not require antiviral therapy. The 
decision of whether to initiate antiviral therapy for each 
patient should be based upon the clinician's judgment and on 
what is known about the benefits of therapy for seasonal 
influenza. 
Timing of antiviral initiation:  
 Treatment should be initiated as soon as possible since 
antiviral therapy is most likely to provide benefit when 
initiated within the first 48 hours of illness.  
 Treatment should not be delayed while awaiting the results of 
diagnostic testing.  
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 Furthermore, patients who have a negative rapid antigen test 
for influenza but in whom the clinical suspicion for influenza 
infection is high should be treated with antivirals since the 
sensitivity of these tests is generally low.  
Steps to reduce delays in treatment initiation: 
 Informing patients at increased risk for complications of the 
signs and symptoms of infection and the importance of early 
initiation of therapy  
 Ensuring rapid access to telephone consultation and clinical 
evaluation for patients at high risk for complications and 
those with severe influenza  
 Considering empirical  treatment of patients at high risk for 
complications based on telephone contact  
 Considering certain patients at high risk for complications  
(eg, patients with neuromuscular disease) with prescriptions that could 
be filled following telephone consultation with a healthcare provider.  
Choice of antiviral: 
 For patients requiring treatment, zanamivir or oseltamivir is 
recomended (48). Zanamivir is contraindicated in patients 
with asthma or chronic obstructive pulmonary disease.  
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 During this pandemic, in patients suspected to have influenza, 
neuraminidase inhibitor (zanamivir or oseltamivir) is 
recommended (48).  
 However, if surveillance data indicate that oseltamivir-
resistant seasonal H1N1 influenza A virus is circulating 
zanamavir should be given instead of oseltamavir. 
  In such a setting, for patients who are unable to take 
zanamivir,  the addition of rimantadine (or, less preferably, 
amantadine) to oseltamivir (48) should be done .  
 Of note, prior to the emergence of pandemic H1N1 influenza 
A, the majority of seasonal H1N1 influenza A isolates in the 
United States were resistant to oseltamivir.  
Dosing: 
 The dosing of antivirals for the treatment of pandemic H1N1 
Influenza A infection in adults is the same as for seasonal 
Influenza. Zanamivir inhalation powder should not be 
reconstituted in any liquid formulation and is not 
recommended for use in nebulizers or mechanical ventilators (62). 
 Antiviral therapy should be continued for five days, as with 
seasonal influenza. 
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 The US Centers for Disease Control and Prevention note that some 
experts have advocated increased (doubled) doses of oseltamivir 
and that hospitalized patients with severe infections might require 
longer treatment courses, although the possible benefit of these 
approaches has not been adequately studied. 
Other Drugs Under Evaluation: 
 Peramivir and other cyclopentane derivatives: A single 
injection in mice strongly suppreses influenza virus. 
 Dimeric Neuraminidase Inhibitors: It is 100 times more 
potent than Zanamivir. It also opens possibility of once a 
week dose. 
 Ribavarin and Interferon alpha.  
 Sialidase fusion proteins & siRNAs. 
VACCINATION 
General consideration for vaccination: 
 H1N1 influenza vaccine elicit less immune response than 
seasonal vaccine.                         
 Whole virus vaccine appear to be more immunogenic than 
split or subunit vaccine. 
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 Adjuvant may reduce the amount of antigen required. 
 Vaccine produced from one clad may confer cross reactivity 
with other clads but this is likely to  decrease with further 
evolution of virus. 
Problems with vaccines: 
 Production facilities are limited. 
 Mutations keep on occurring in Influenza - A viruses so we 
cannot be sure of viral strain for which vaccine is to be 
produced. 
 It is very difficult to produce vaccine against H1N1. 
 Vaccine is unlikely to be available during initial 4 to 6 weeks 
of a new pandemic. 
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PERSONAL PROTECTIVE EQUIPMENT 
 Gloves 
 Gowns 
 Masks 
 Boots 
 Eye protection 
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GLOVES 
 
Different kinds of gloves:  
 Housekeeper gloves  
 Clean gloves  
 Sterile glove 
Precautions while using gloves: 
 Work from clean to dirty. 
 Avoid touch contamination with eyes, mouth, nose and  body 
surfaces. 
 Change gloves between patients. 
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GOWNS 
 
ADVANTAGES  
 Fully covers torso. 
 Has  long sleeves. 
 Fits  snuggly at the wrist. 
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MASKS AND RESPIRATORS 
 
Particulate respirators (N95) 
 Fit testing  is essential 
 Very effective in preventing H1N1 infection. 
BOOTS 
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EYE PROTECTION 
 
Advantages:  
 Shields  face  
 Goggles protects eyes 
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PRECAUTION 
Precaution Levels:  
 Standard Precautions  
 Contact Precautions 
 Droplet Precautions 
 Airborne Precautions 
 
Standard Precautions: 
 Prevent the transmission of common infectious agents 
 Hand washing is important  
 Assume infectious agent could be present in the patient’s  
o Blood  
o Body fluids, secretions, excretions 
o Non-intact skin 
o Mucous membranes 
Hand Washing: 
 Wet hands with clean (not hot) water 
 Apply soap 
 Rub hands together for at least 20 seconds 
 Rinse with clean water 
 Dry with disposable towel or air dry 
 Use towel to turn off faucet. 
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Contact Precautions:  
(Prevent infection through direct or indirect contact with 
patients or patient care environment) 
 Limit patient movement 
 Isolate or cohort patients 
 Gown + gloves for patient  / room contact 
o Remove immediately after contact 
o Do not touch eyes, nose, mouth with hands  
o Avoid contaminating environmental surfaces 
Droplet Precautions: 
 Wear surgical mask within 1 meter of patient 
 Wear face shield or goggles within 1 meter of patient 
 Place patients in single rooms or cohort 1 meter apart 
 Limit patient movement within facility 
 Patient wears mask when outside of room 
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NEGATIVE PRESSURE ISOLATION ROOM 
 
CONTAINMENT AND INFECTION CONTROL 
 Timely recognition and high index of suspicion with 
continuous monitoring and surveillance  
 Quarantine of the exposed persons 
 Implementation of standard infection control precautions. 
 Droplet precautions: Larger particle droplets (>5µm in size) - 
generated during coughing, sneezing, talking or the 
performance of procedures. 
 Contact precautions 
 For aerosol generating procedures – Airborne precautions   
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VIRUS INACTIVATION AND DISINFECTION 
 Surfaces contaminated with secretions or fluids should be 
cleaned daily 
 Damp dusting  should be done rather than dry dusting 
 Disinfectants that can be used: 
o Phenolic disinfectants 
o Quaternary ammonia compounds 
o Peroxygen compounds 
o Sodium hypochlorite (household bleach) 
o Alcohol (Ethyl alcohol) 
Note: 
o Do not spray (i.e. fog) with disinfectant  
o Virus is killed by heat (56*c for 3 hrs or 70*c for 30 
minutes) 
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OCCUPATIONAL HEALTH 
 Prompt recognition  of healthcare workers with influenza like 
illness and those who are symptomatic should be evaluated 
and excluded from duty 
 Develop a system to monitor work absenteeism for health 
reason    
 Those staff caring for influenza patients should not be posted 
elsewhere 
 Availability of antiviral agents for treatment of exposure. 
EDUCATION AND TRAINING 
 Infection control procedures should be discussed. 
 Modes of transmission of the pathogen should be explained. 
 Attention to respiratory hygiene should be reinforced by 
displays of posters. 
 Importance of reporting symptoms to authorities should be 
explained 
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MATERIALS AND METHODS 
SETTING 
Patients admitted with diagnosis of H1N1 influenza 
pneumonia  in the   Institute  of Internal Medicine, Rajiv Gandhi 
Government General Hospital, Chennai and Institute of child 
health, Chennai were evaluated in the study. 
COLLABORATING DEPARTMENTS: 
Institute of Internal Medicine ,  Madras Medical College 
Institute of Child Health, Madras Medical College 
Institute of Microbiology, Madras Medical College 
ETHICAL COMMITTEE APPROVAL 
Institute Ethical Committee approved the study. 
STUDY DESIGN :  Case series Study 
DURATION OF THE STUDY :  6 Months    
SELECTION OF PATIENTS :  Sample Size - 442 Patients  
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INCLUSION CRITERIA: 
1) Patients with suspected symptoms of influenza like illness 
admitted in Institute of Internal Medicine, Rajiv Gandhi 
Government General Hospital, Chennai and Institute of child 
health. 
2) Proven cases of H1N1 influenza admitted in Rajiv Gandhi 
Government General Hospital, Chennai and Institute of child 
health. 
EXCLUSION CRITERIA 
1) Patients who are negative for H1N1 influenza. 
2) Patients who are not willing for the study 
CONSENT 
Informed Consent obtained from all the patients. 
CONFIRMATION OF INFLUENZA 
It was done by RT-PCR in King Institute, Guindy, Chennai. 
STUDY PATTERN 
Prospective study. 
DATA ANALYSIS 
Data analysis was done using SPSS and Epi-info software. 
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METHODOLOGY 
A  hospital based  case series study was conducted in 
government general hospital, Chennai and  in Institute of child health, 
Egmore, Chennai, India  prospectively from August 09  upto January 
2010. The study had ethical clearance from the Institutional ethical 
committee. All suspected cases were confirmed by RT-PCR performed 
at the King institute laboratory, Guindy, Chennai.  A  total  number of 
442 H1N1 positive patients (198 inpatients and 244 outpatients)  from 
two government hospitals in Chennai ,Madras Medical College & 
Government General Hospital  and  Institute Of Child Health, Egmore 
were studied prospectively  during a period  of 6 months from August 
2009 to January 2010.A confirmed case of pandemic H1N1 influenza 
A is defined as an individual with an ILI with laboratory-confirmed 
H1N1 influenza  A virus detected by real-time reverse transcriptase 
(RT)-PCR or culture. During this period the clinical profile of H1N1 
cases was analysed with reference to age distribution, sex distribution, 
time distribution, clinical manifestations, risk factors, complications 
etc.  Detailed physical examination and other investigations like 
complete blood count, renal function test, liver function test, ECG, 
chest X ray was done for all persons. Data was analyzed using 
statistical SPSS software  and using chi square test. 
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Statistical analysis: 
Following statistical methods have been employed in the 
present study. 
 Independent samples ‘t’ test-Unpaired. 
 Independent samples ‘t’ test-Paired. 
 One-way Analysis of Variance (ANOVA). 
 Pearson correlation coefficient. 
 Relative risk. 
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OBSERVATION AND RESULTS 
CASES DISTRIBUTION  
TABLE-1 
S.NO CASES MMC ICH 
1. OUT PATIENT 80 162 
2. IN PATIENT 133 67 
TOTAL CASES 213 229 
CASES DISTRIBUTION  
CHART-1 
 
 
ICH – Institute of Child Health (Paediatric Cases) 
MMC – Madras Medical College (Adult Cases) 
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TIME WISE DISTRIBUTION OF CASES 
 The epidemic peaks in September and December correlated 
with the rains and chill climate that prevailed at that time in 
Chennai city.             
TIME WISE DISTRIBUTION OF CASES  
TABLE -2 
S.NO TIME PERIOD CASES 
1. JULY 1-JULY 31  0 
2. AUGUST 1-AUGUST15  1 
3. AUG 16 –AUG 31  53 
4. SEP 1-SEP15  116 
5. SEP16 –SEP30  90 
6. OCT1 –OCT 15  51 
7. OCT 16 –OCT31  20 
8. NOV 1-NOV 15  12 
9. NOV 16-NOV 30  27 
10. DEC1 –DEC 15  50 
11. DEC 16– DEC 31  19 
12. JAN 1 –JAN  15  1 
13. JAN 16- JAN 31  2 
 TOTAL  CASES  442 
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TIME WISE DISTRIBUTION OF CASES  
CHART -2 
 
A characteristic M pattern was observed in the time 
distribution of swine flu cases. This is similar to the pattern 
observed in the 1918  spanish flu pandemic. 
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AGE WISE DISTRIBUTION OF TOTAL CASES  
TABLE - 3 
S.NO AGE GROUP NUMBER OF CASES PERCENT-CASES
1. 0-5 98 22.17% 
2. 5-25 243 54.97% 
3. 25-49 79 17.87% 
4. 50-65 19 4.29% 
5. >65 3 0.67% 
 TOTAL 442  
 
COMPARATIVE ANALYSIS OF OUR AGE DISTRIBUTION 
OF  TOTAL CASES WITH U.S DATA 
CHART -3 
 
Maximum cases were reported in the age group of 5-25 years 
in our study as well as in the United States study 
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AGE DISTRIBUTION OF  TOTAL CASES – U.S   DATA 
TABLE-4 
S.NO AGE DISTRIBUTION PERCENT OF  CASES 
1. 0-5 37.07% 
2. 5-25 43.22% 
3. 25-49 11.28% 
`4. 50-65 6.31% 
5. >65 2.10% 
COMPARATIVE ANALYSIS OF OUR AGE DISTRIBUTION 
OF HOSPITALISED CASES WITH U.S DATA  
CHART-4 
 
In US population, maximum no.of H1N1 swine flu influenza 
cases requiring hospitalisation were reported in the age group of  
(0-5 years) where as in our study, maximum hospitalised cases were 
documented  in the age group of 5-25 years. 
 53
HOSPITALISED PATIENTS  
TABLE-5 
 
AGE WISE DISTRIBUTION OF HOSPITALISED  PATIENTS-
U.S DATA  
TABLE -6 
S.NO AGE DISTRIBUTION PERCENT OF PATIENTS 
1. 0-5 42.45 
2. 5-25 19.81 
3. 25-49 10.37 
4. 50-65 11.02 
5. >65 16.03 
 
S.NO AGE DISTRIBUTION 
CASES 
NUMBER 
PERCENTAGE OF 
Cases 
1. 0-5 34 17.08% 
2. 5-25 100 50.25% 
3. 25-49 52 26.13% 
4. 50-65 10 5.02% 
5. >65 3 1.05% 
TOTAL NUMBER 199  
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ADULT TOTAL NUMBER OF CASES 
CHART -5 
 
 
CHILDREN – TOTAL NUMBER OF CASES  
CHART -6 
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SEX DISTRIBUTION  
TABLE-7 
H1N1 cases were equally  distributed in both the  sexes in the 
adult population (male -111, female-102). But in the paediatric 
population there was an apparent increase in male cases. This was 
due to increased rate of admissions of male children when 
compared to female children. 
 CHILDREN ADULT TOTAL 
MALES  144 102 246 
FEMALES  85 111 196 
TOTAL 229 213 442 
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CLINICAL MANIFESTATIONS 
TABLE 8 
Symptoms Percent Symptoms Percent Symptoms Percent
1.Fever  95.45% 7.Breathlessness 32.82% 13.Diarrhoea 8.08% 
2.Chills 
and rigor 
18.18% 8.Expectoration 33.33% 14.Seizure 1.01% 
3.Nasal 
discharge 
14.14% 9.Bodyache 20.20% 15.Oliguria 0.50% 
4.Ear 
discharge 
0 10.Headache 26.26% 16.Abdominal 
pain 
1.51% 
5. Cough  82.32% 11.Fatigue 10.1%   
6.Sore 
throat 
26.76% 12.Vomitting 17.17%   
 
CLINICAL MANIFESTATIONS  
CHART- 7 
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INFLUENZA   LIKE  ILLNESS  
TABLE - 9 
S. 
No Clinical  Picture 
All 
patients 
Pnuemonia 
patients 
1. INFLUENZA LIKE ILLNESS 87.12%  80.48%  
2. FEVER+ COUGH/ SORETHROAT/ 
BREATHLESSNESS 
89.39%  87.80%  
 
INFLUENZA LIKE ILLNESS  
CHART -8 
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RISK FACTORS   
CHART -9 
 
 
RISK FACTORS   
TABLE 10 
RISK FACTOR PERCENTAGE OF CASES 
POPULATION 
PREVALENCE 
P 
value 
ASTHMA 16% 2.38% . ref(5) <0.01 
TUBERCULOSIS 8.8% 0.4% <0.01 
HYPERTENSION 7.2% 8.4%  
DIABETES 6.4% 4%  
Note: Asthma and TB were found to be risk factors for the 
occurrence of H1N1 swine flu influenza. 
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COMPLICATIONS PAEDIATRIC AGE GROUP 
CHART 10 
 
COMPLICATIONS ADULT 
CHART 11 
 
Note: Exacerbation – Exacerbation of Asthma
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COMPLICATIONS  ADULT  
TABLE-11 
S. No Complications (Adult) Percent (n=199) 
1.  URI-SINUSITIS  1.6% 
 EXACERBATION OF BRONCHITIS, 
BRONCHIAL  ASTHMA  
1.6% 
2.  PNUEMONIA  32.8% 
3.  MUSCULOSKELETAL-
MYALGIA,ARTHRITIS  
4.8% 
4. SKIN MANIFESTATIONS 1.6% 
 
COMPLICATIONS-PAEDIATRIC AGE GROUP  
TABLE -12 
S. No Complications Percent (n=66)
1. EXACERBATION  OF BRONCHITIS,
BRONCHIAL  ASTHMA 
10.60% 
2. PNUEMONIA 19.69% 
3. SKIN MANIFESTATIONS 1.6% 
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MORTALITY RATES  
CHART 12 
 
 
MORTALITY RATES  
TABLE- 13 
 
CONDITION MORTALITY  RATES 
1.OVERALL MORTALITY 1.8% (8 out of 442) 
2.MORTALITY IN PNUEMONIA 14.63% (8 out of 54) 
3.MORTALITY IN PREGNANCY 25% ( 3 out of 12) 
4.MORTALITY IN  FETUS 16.66% (2 out of 12) 
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X RAY CHEST OF THE  H1N1 SWINE FLU PATIENT WITH 
BILATERAL  PNEUMONIA 
 
 
CT CHEST DEMONSTRATING BILATERAL PNEUMONIA                 
IN H1N1 SWINE FLU PATIENT 
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VENTILATOR USED  
CHART- 13 
 
 
VENTILATOR NOT USED   
CHART -14 
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VENTILATOR REQUIREMENT  AND OUTCOME  
TABLE-14 
 ALIVE DEAD TOTAL 
VENTILATOR USED 2 8 10 
NOT USED 189 0 189 
Total 191 8 199 
Ventilator requirement was an independent risk factor 
correlating with higher mortality rate  and poor prognosis in H1N1 
patients. P value<0.01.  
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H1N1 INFECTION AND PNEUMONIA:  
The x rays of the pneumonia patients that was analyzed 
showed that there was a predominance of  lower lobe involvement 
(p value <0.01). 50% - lower lobe , 5.2% - upper lobe , 18% - 
middle lobe , bilaterality -100%. Similar findings have been 
observed in studies in brazil (73) . The predominance of lower lobe 
involvement was probably due to the gravitational bias in blood 
supply. Pneumonia as  a complication  was more common  in the 
age group of  25-49 ie  53.4%, it was equally reported  in both 
sexes (men 21,women 20). 
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X RAY FINDINGS  IN PNEUMONIA 
TABLE 15  
S. No X ray Findings Number Percent 
1. Predominant involvement of upper 
lobe only 
2 5.2% 
2. Predominant involvement of middle 
lobe 
2 5.2% 
3. Involvement of lower lobe only 14 36% 
4. Involvement of both middle lobe and 
lower lobe 
5 13% 
5. All lobes involved diffusely (random 
involvement ) 
15 38.3% 
TOTAL NUMBER OF CASES  38  
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H1N1 INFLUENZA AND PERIOD OF PREGNANCY  
CHART-15 
 
 
PREGNANCY AND H1N1 EPIDEMIC RELATION TO 
PERIOD OF PREGNANCY  
TABLE-16 
Period of pregnancy No  of cases(n=12) Percent 
First trimester  2 16.67% 
Second trimester  0 0 
Third trimester  10 83.33% 
Total no. of cases 12  
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PREGNANCY AND MORTALITY IN H1N1 SWINE FLU 
CHART 16 
 
 
NON PREGNANT STATE AND MORTALITY IN SWINE FLU 
CHART 17 
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PREGNANCY AND MORTALITY 
TABLE 17. 
H1N1 INFECTION DEATH ALIVE  
PREGNANT 3 9 12 
NON-PREGNANT 5 181 186 
TOTAL 8 190 198 
 
 
PREGNANCY AND COMPLICATIONS 
TABLE 18 
H1N1 
INFECTION PNEUMONIA
NO 
PNEUMONIA  
PREGNANT 9 3 12 
NONPREGNANT 45 141 186 
TOTAL 54 144 198 
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H1N1 INFECTION IN PREGNANCY AND COMPLICATIONS 
CHART 18 
 
H1N1 influenza occuring in pregnancy is associated with a 
higher mortality and more complications. P value--<0.001** 
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DISCUSSION  
The current H1N1 pandemic had witnessed more number of cases 
in the age group of 5-25 years which is unusual in the conventional 
seasonal flu. Hospitalisation rates were more common in our study  
in the age group of 5-25 years but in U.S it is more common in the 
extremes of age group (72, 64, 67). In our study  86.92% percent of 
patients with pandemic H1N1 influenza A  have met the case 
definition for influenza like illness (subjective fever plus cough 
and/or sore throat) whereas it was 95% in New York City. (65).  
Fever ,cough, sorethroat ,breathlessness were the most common 
symptoms observed in our population with H1N1 infection which is 
similar to that of the U.S studies. [64].In contrast, approximately 
one third of patients seen at two hospitals in Mexico had no fever at 
presentation. 
The prevalence of certain underlying conditions was 
significantly higher among 198 patients requiring hospitalization 
for pandemic H1N1 Influenza A in our study than in the general 
population. Bronchial asthma and tuberculosis were found to be 
risk factors. Seizure disorder was reported in 3% of persons, 
cardiac lesion was seen in 2% of persons and persons with 
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immunosuppressive conditions accounted for 1% of the total cases 
.Smoking was reported in 8% of cases and alchoholism reported in 
10.4% of cases. Similar picture was observed in the United states 
where 32 percent of these patients had asthma compared with only 
8 percent of the US population. Out of the 133 patients requiring 
hospitalization, 80 percent of the persons had the underlying 
condition that increased the risk of influenza complications. Of 272 
patients requiring hospitalization in the United States, 73 percent 
had at least one underlying condition that increases the risk of 
influenza complications (68). 
Few elderly individuals have been infected ie (0.67% in 
persons>65 years), which may be due to some degree of preexisting 
immunity in older individuals against antigenically similar 
influenza viruses. However, elderly individuals who are infected 
are still thought to be at increased risk for complications. In our 
study, approximately 25% (2 out of 8) of deaths caused by 
pandemic H1N1 influenza A virus in the study have occurred in 
pregnant women, although only 2.1 percent of the population is 
pregnant at any given time (63). During prior influenza epidemics 
and pandemics, as well as during the current pandemic, pregnant 
women have had increased morbidity and mortality (69). The 
 73
mortality rate among pregnant women in the U.S among H1N1 
influenza cases has been around 28% ( 71).Similarly in our study  
mortality rate in H1N1 influenza in pregnancy was found to be 
25%. (3 out of the 12) . During previous influenza pandemics, 
increased rates of spontaneous abortion and preterm birth have been 
reported among pregnant women, especially in those with 
pneumonia (71). Out of the 12 pregnant women requiring 
hospitalization in our study two had spontaneous abortion following 
intrauterine death in the third trimester. The fetal loss rate was 
16.67% (2 out of 12). Similar to our analysis, studies in other 
countries have also reported an increased risk of  influenza among 
pregnant women , particularly during the third trimester (70). 
 74
CONCLUSION 
 The rate of reported cases and hospitalization rates were 
highest among individuals aged 5 to 24 years.  
 H1N1 cases were equally  distributed in both the sexes in the 
adult population    
 In our study  86.92%  of patients with pandemic H1N1 
influenza A  met the case definition for influenza like illness 
(subjective fever plus cough and/or sorethroat ). 
 Similar  to the western data  bronchial asthma ,pulmonary 
tuberculosis were found to risk factors for complications 
in  H1N1 infection. The overall mortality rate was 1.8% and 
the  most common cause of death in patients was due to 
pneumonia. 
 Ventilator requirement was associated with  poor prognosis in 
H1N1 patients.  P value <0.01. 
 The  percentage of persons > 65 years who were affected  
was far  less ie 0.67% which is quite unusual in the case of 
seasonal flu . 
 75
 H1N1 pnuemonia  was  found  to involve  predominantly  
the  lower lobe of  lung.( p value <0.01). 
 The  mortality rate among pregnant women with H1N1 
infection  was 25%  and the fetal  loss rate was 16.67%.  
 There was an increased risk of H1N1 influenza infection 
during the  third trimester of pregnancy. (p value-0.027)  
 The clinical profile of H1N1 influenza that was observed in 
our study was  similar to that of the western data with some 
differences.  
 Individuals with comorbid conditions, pregnancy were found 
to  be severely affected.  Hence individuals with risk factors  
need to be protected by  vaccination.. 
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LIMITATION OF THE STUDY 
This study was basically conducted as a prospective study in 
a tertiary care institute. Hence the milder forms of the infection as 
well as the index case which occurred at the community level could 
have been missed out. Hence this analysis may not reflect the actual 
distribution of the cases at the population level. Further community 
based studies are required to analyse the actual impact of H1N1 
infection in the community. 
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CASE RECORD FORM 
NAME OF THE PATIENT 
AGE                                                  
SEX 
ADDRESS 
SOCIOECONOMIC STATUS 
EDUCATIONAL STATUS 
MONTHLY INCOME 
CLINICAL MANIFESTATIONS 
DATE OF ILLNESS ONSET  
DATE OF FEVER ONSET 
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MAIN PRESENTING COMPLAINTS: 
 
SYMPTOMS 
 
YES
 
NO
 
DURATION
 
COMMENT
1.Sudden onset of 
symptoms<12hours  
    
2.fever      
3.chills and rigor     
4.nasal discharge     
5.ear discharge     
6. cough     
7.sore throat     
8.breathlessness     
9.expectoration     
10.headache     
11.bodyache     
12.fatigue     
13.ARI in family in last 2 
weeks 
    
14.concomitant illness     
15.vomitting     
16.diarrhoea     
17.seizure     
18.other symptoms 
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Anyone at home having similar illness       Yes/no 
Any recent history of foreign travel           yes/no 
How many days of work or school have you missed 
Have you visited someone else to treat your illness prior to 
this visit 
PAST HISTORY: 
Any history of tuberculosis ,bronchial asthma, systemic 
hypertension,  diabetes or other comorbid condition in the 
patient. 
PERSONAL HISTORY: 
H/O smoking, alchoholism, in the patient. 
Is the occupation of the patient related to poultry or with 
people working with poultry in the last 2 weeks. 
FAMILY HISTORY: 
Any history of similar episodes in the family   members. 
GENERAL EXAMINATION: 
 VITALS 
EXAMINATION OF RESPIRATORY SYSTEM 
 95
EXAMINATION OF UPPER RESPIRATORY SYSTEM: 
NASAL MUCOSA ,TONSILS ,PHARYNX 
EXAMINATION OF THE CARDIOVASCULAR SYSTEM 
EXAMINATION OF THE CNS 
EXAMINATION OF THE ABDOMEN 
COMPLICATIONS 
S.No COMPLICATIONS Present/not
1. URI -sinusitis, otitis media, croup  
2. LRI-pneumonia, bronchiolitis, status 
asthmaticus 
 
3. Cardiac-myocarditis, pericarditis  
4. Musculoskeletal -myositis, rhabdomyolysis  
5. Neurologic acute and post-infectious 
encephalopathy, encephalitis, febrile seizures, 
 
6. Toxic shock syndrome  
7. Secondary bacterial pneumonia with or without 
sepsis. 
 
8. Other complications  
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TREATMENT DETAILS 
*Was tamiflu given or not ? yes/no 
*How many days was tamiflu given ? 
*Did you feel any improvement of symptoms? 
 Some improvement / no improvement /complete  
improvement 
*after how long you felt the improvement of symptoms? 
* any additional  side effect patient felt due to that drug? 
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